Download confusion and agitation

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project

Document related concepts
no text concepts found
Transcript
DELIRIUM
RECOGNITION
AND
MANAGEMENT
DR AISLING O’GORMAN
Consultant in Palliative Medicine
LOUTH & MEATH SPECIALIST PALLIATIVE CARE SERVICES
DELIRIUM

The entity formally known as ….
–
–
–
–
Confusion & agitation
- Organic psychosis
Acute confusional state
- Opioid toxicity
Cognitive impairment / failure
Acute brain syndrome
- ITU encephalopathy
2
DELIRIUM

An aetiologically non-specific, global, cerebral
dysfunction characterised by concurrent
disturbance of level of consciousness,
attention, thinking, perception, memory,
psychomotor behaviour, emotion and the
sleep-wake cycle.
3
Confused ????
Delirium = Brain Failure
DELIRIUM

An aetiologically non-specific, global, cerebral
dysfunction characterised by concurrent
disturbance of level of consciousness,
attention, thinking, perception, memory,
psychomotor behaviour, emotion and the
sleep-wake cycle.
5
Delirium Subtypes

Hyperactive
 Hypoactive
 Mixed
Hypoactive
Mixed
Hyperactive
Delirium – What’s it to YOU ???
Delirious patients





Stop eating
Stop drinking fluids
Stop taking important medications
May fall and injure themselves
Are often placed in restraints and suffer
complications such as aspiration and
decubitus

Morbidity:
– Associated with prolonged hospitalisation
– More hospital-acquired complications e.g.
falls & pressure sores
– Increased risk of long term cognitive
decline
– More likely to require admission to long
term care
– Loss of independent living
Delirium Is Deadly !!!

Mortality rates:
– 10% - 65%
But
- With appropriate management, may be
reversible in up to 50%
DELIRIUM

Prevalence:
– 10% - 35% of hospitalised patients

Elderly Patients
– 30% of hospitalised elderly

Cancer Patients
– 25% - 40% of cancer patients
– Up to 85% of cancer patients with
advanced disease
10
Risk FactorAssessment for Delirium

Age 65 yrs or older
 Cognitive impairment (past or present)
 Current hip fracture
 Severe illness
11
Mental Health Problems among
elderly in hospitals







50% cognitive impairment
27% delirium
8-32% depressive illness
6% hallucinations
8% delusions
21% apathy
9% agitation/aggression
Goldberg et al; Age Ageing 2011 Sep 1

Elderly patients with mental health
problems in hospital
– 47%
– 49%
– 44%
Incontinent
Assistance with feeding required
Major assistance to transfer
Goldberg et al; Age Ageing 2011 Sep 1
Delirium – Differential Diagnosis

Dementia
 Depression
 Mania
 Psychosis
DELIRIUM
DEMENTIA
Acute.
Chronic.
Often remitting &
Usually progressive
reversible.
& irreversible.
Mental clouding.
Brain damage.
(info not taken in)
(info not retained)
Poor concentration
Impaired short term memory
Disorientation
Living in past
Misinterpretations
Hallucinations
Delusions
15
DELIRIUM
DEMENTIA
Speech rambling &
incoherent.
Speech
stereotypes &
limited.
Often diurnal
variation.
Constant
(in later stages).
Often aware &
anxious.
Unaware &
Unconcerned
(in later stages).
16
17
18
Pathophysiology of Delirium







↓ Acetylcholine
↑ Dopamine
↑ Noradrenaline
↑ Serotonin
↓ Histamine
Gaba
Cytokines- IL-1,
IL-2,6; TNF; IF
Recognising Delirium - Indicators

Recent changes or fluctuations in
behaviour
– Cognitive function
– Perception
– Physical function
– Social behaviour
Clinical Features






Acute onset
Fluctuating course
Inattention
Disorganised
thinking
Altered
consciousness
Cognitive deficit

Perceptual
disturbance
 Psychomotor
disturbance
 Altered sleep-wake
cycle
 Emotional
disturbance
ESSENTIAL CRITERIA FOR
DIAGNOSING DELIRIUM

Disturbance of consciousness / impaired
attention.
 Change in cognition
 Acute / subacute onset & fluctuating course
 Evidence of general medical condition judged
to be aetiologically related to the disturbance.
DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS IV
22
Consciousness

Level of consciousness = awake/alertness

Content of consciousness = awareness
Hypoalert
Hyperalert
Attention

Inability to direct,
focus and sustain
attention
– Distractable
– Neglect
– Perseveration

Serial 7’s
 Count down 20-1
 ‘WORLD’–‘DLROW’
 Digit span forward &
backwards

Linked to arousal/
consciousness
Registration of new information does not occur –>
immediate & short term memory loss
Change in Cognition

Disorganised thinking
– Memory deficit
– Disorientation
– Language disturbance
– Perceptual disturbance
Bedside Tests

Cognitive Tests – MMSE
– SOMCT

Tests to Differentiate Delirium from Dementia
– DRSR-98
– MDAS

Tests for Delirium
–
–
–
–
Cognitive Test for Delirium
DRS – R-98
CAM – Confusion Assessment Method
NUDESC
Management of Delirium
SOLVE THE PROBLEM !!!!
 Treat the underlying causes
 Environmental interventions
 Antipsychotics

– Haloperidol, risperidone, quetiapine,
olanzapine,
CAUSES OF DELIRIUM

Drug Toxicity

Direct CNS Causes

Infection

Hypoxia

Surgery

Environmental

Metabolic

Paraneoplastic
encephalopathy

Haematological
Electrolyte

Elimination disorder

28
Delirium - Causes
– Medications
•
•
•
•
•
•
•
•
Chemotherapy
Steroids
Radiotherapy
Opioids
Benzodiazepines
Anticholinergics
Antiemetics
Withdrawal
MANAGEMENT OF DELIRIUM

Assess patient:
–
–
–
–
–
–
–
Determine cause
? Potentially reversible factors
Check list
History (NB collateral)
Examination
Review medication
Blood tests
30
MANAGEMENT OF DELIRIUM

Environmental
Interventions:
–
–
–
–
Supportive measures
Keep to a routine
Quiet & well lit room
Orientate patient
frequently
– Separate past & present
– Explanations to patient
– Identify & respond to
mood
– Avoid unnecessary
confrontation
– Avoid restraints
– Courtesy & respect
– Presence of family
member/close friend
31
MANAGEMENT OF DELIRIUM

Communicate with family:
– Clear explanation of goals of management
& possible outcomes.
32
MEDICAL MANAGEMENT OF
DELIRIUM

There are 3 distinct clinical entities:
– Hyperactive: Agitated
– Mixed: Hypoactive – Hyperactive
– Hypoactive – Hypoalert, withdrawn,
confused
33
MEDICAL MANAGEMENT OF
DELIRIUM

Haloperidol:
– Highly potent dopamine
blocking agent
– Half life: 20 hours
– Minimal anticholinergic
V/E
– Less sedating than
phenothiazines
– Administration:
• Po, iv, im, sc
– Dose:
•
•
•
•
•
1-2 mg po/sc q 6 hrly
Elderly 0.5 – 1mg bd
1 mg q 1 hrly prn
Titrate as needed
Higher doses may be
required initially, if
severely agitated
• Rarely exceed 20mg /
24 hours
34
MEDICAL MANAGEMENT OF
DELIRIUM
NEW ATYPICAL ANTIPSYCHOTICS

Olanzapine
• Fewer Extrapyramidal
V/E
• Dose 2.5mg stat, prn
• Available in Velotab
preparation
• V/E – Drowsiness &
Weight Gain, ACH

Risperidone
• Dose 500mcg bd &
prn
• Increase by 500mcg
bd on alt days
• Median maintenance
dose – 1mg/day

Quetiapine
• Dose 12.5 – 25mg bd
35
MEDICAL MANAGEMENT OF
DELIRIUM

Methotrimeprazine:
– Dose:
– Widely used in
terminal stages
– V/E:
• sedating
• postural hypotension
• 6.25mg – 12.5 mg
sc/po q 8-12h
• Higher doses in
terminal stages:
– 12.5 mg – 25 mg
sc/po q 4 – 8 hrly
– Up to 300 mg / 24
hours via syringe
driver reported
36
MEDICAL MANAGEMENT OF
DELIRIUM

Chlorpromazine:
– Useful oral alternative when some sedation is
desirable
– Dose: 25mg po q 8 hrly

Midazolam:
– Rapid onset & short half life
– Administration: iv, im, sc
– Dose: 2.5 mg – 10 mg stat followed by
20mg – 100 mg / 24 hours

Phenobarbitone:
– Pre terminal agitation
– Used with midazolam
– Dose: 200 mg – 800 mg / 24 hours
37
Delirium and Suffering in the Dying
Patient

Suffering caused by delirium is hard to assess,
even retrospectively.
 Interferes with meaningful contact
 Distressing to families
 Visions and visitation on the deathbed:
-Pathologic?
-Supernatural?
38
Delirium at End of Life
Treatment Overview
 Primary Goals:
-Maximizing Patient Comfort
-Minimizing Patient (Family) Distress
 Tx Underlying Cause (When Possible & Appropriate

Usually involves Medication:
-Benzodiazepines
-Neuroleptics

May Require Heavy Sedation
39
TERMINAL DELIRIUM









Delirium occuring in last days of life
Cause – multifactorial, unknown
Investigations – limited
Focus – Patient comfort
NB General measures
Haloperidol 10 – 30mg/24hrs
Methotrimeprazine 50 – 200mg/24hrs
Phenobarbitone 800 – 1600mg/24hrs
+/- Midazolam 10 – 100mg/24 hrs
40
CONCLUSION






Prevention / Minimise Risk
Early Diagnosis
Early Treatment
Careful Systematic Approach
Correct Reversible Causes
NB General Measures
41
References

Inuoye S. Delirium in Older Persons. NEJM. 2006; 354:1157-65

Centeno C, Sanz A,Bruera E. Delirium in advanced cancer
patients. Palliat Med. 2004; 18: 184-94

Lawlor P et al. Occurrence, Causes and outcome of delirium in
patients with advanced cancer. Arch Intern Med; 160: 786-94

Caraceni A, Simonetti F. Palliating delirium in patients with
cancer. The Lancet. 2009: 10; 164-72

Lonergan E et al. Antipsychotics for delirium. Cochrane
Database Syst Rev. 2007 Apr 18;(2):CD005594
References

Grover S, Matoo SK, Gupta N. Usefulness of atypical
antipsychotics and choline esterase inhibitors in delirium: a
review. Pharmacopsychiatry. 2011 Mar; 44(2): 43-54

Grover S, Kumar V, Chakrabarti S. Comparative efficacy study
of haloperidol, olanzapine and risperidone in delirium. J
Psychosom Res. 2011. Oct;71(4): 277-81

Delirium: diagnosis, prevention and management. NICE clinical
guideline 103.